Andre P, Denis C, Soulas C, Bourbon Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018;175:1731-1743.e13 pubmed publisher

Wang E, Pjechova M, Nightingale K, Vlahava V, Patel M, Růcková E, et al. Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses. Proc Natl Acad Sci U S A. 2018;115:4998-5003 pubmed publisher

Cribbs A, Hookway E, Wells G, Lindow M, Obad S, Oerum H, et al. Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. J Biol Chem. 2018;293:2422-2437 pubmed publisher

Kaczmarek D, Kokordelis P, Kramer B, Glässner A, Wolter F, Goeser F, et al. Alterations of the NK cell pool in HIV/HCV co-infection. PLoS ONE. 2017;12:e0174465 pubmed publisher

Fielding C, Weekes M, Nobre L, Růcková E, Wilkie G, Paulo J, et al. Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation. elife. 2017;6: pubmed publisher

Willemen Y, Van den Bergh J, Bonte S, Anguille S, Heirman C, Stein B, et al. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. Oncotarget. 2016;7:73960-73970 pubmed publisher

Landtwing V, Raykova A, Pezzino G, Beziat V, Marcenaro E, Graf C, et al. Cognate HLA absence in trans diminishes human NK cell education. J Clin Invest. 2016;126:3772-3782 pubmed publisher

Peper J, Bösmüller H, Schuster H, Gückel B, Hörzer H, Roehle K, et al. HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. Oncoimmunology. 2016;5:e1065369 pubmed publisher

Goodier M, Rodríguez Galán A, Lusa C, Nielsen C, Darboe A, Moldoveanu A, et al. Influenza Vaccination Generates Cytokine-Induced Memory-like NK Cells: Impact of Human Cytomegalovirus Infection. J Immunol. 2016;197:313-25 pubmed publisher

Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Mol Med. 2016;8:702-11 pubmed publisher

Wu Z, Frascaroli G, Bayer C, Schmal T, Mertens T. Interleukin-2 from Adaptive T Cells Enhances Natural Killer Cell Activity against Human Cytomegalovirus-Infected Macrophages. J Virol. 2015;89:6435-41 pubmed publisher

Schilling D, Kühnel A, Tetzlaff F, Konrad S, Multhoff G. NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells. Cancer Immunol Immunother. 2015;64:599-608 pubmed publisher

Marquardt N, Béziat V, Nyström S, Hengst J, Ivarsson M, Kekäläinen E, et al. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. J Immunol. 2015;194:2467-71 pubmed publisher

Fionda C, Abruzzese M, Zingoni A, Soriani A, Ricci B, Molfetta R, et al. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. BMC Cancer. 2015;15:17 pubmed publisher

Ohue Y, Kurose K, Mizote Y, Matsumoto H, Nishio Y, Isobe M, et al. Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody. Clin Cancer Res. 2014;20:5052-63 pubmed publisher

Poonia B, Pauza C. Levels of CD56+TIM-3- effector CD8 T cells distinguish HIV natural virus suppressors from patients receiving antiretroviral therapy. PLoS ONE. 2014;9:e88884 pubmed publisher

Nelde A, Walz J, Kowalewski D, Schuster H, Wolz O, Peper J, et al. HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. Oncoimmunology. 2017;6:e1219825 pubmed publisher

Fielding C, Aicheler R, Stanton R, Wang E, Han S, Seirafian S, et al. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathog. 2014;10:e1004058 pubmed publisher